BRCA2 and breast cancer: Although one study suggested a potential, small, non-significant reduction in BCSM in BRCA2 carriers alone following RRSO (HR 0.87, 95%CI 0.32–2.37) [58], the effect, if true, is small, and the overall paucity of published data on BCSM in BC-affected BRCA2 carriers precludes the ability to perform a subgroup analysis.